Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors

PURPOSE: To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of intravenous (IV) irinotecan when administered together in children with refractory solid tumors. To assess the effect of gefitinib on the ph...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Furman, Wayne L., Navid, Fariba, Daw, Najat C., McCarville, M. Beth, McGregor, Lisa M., Spunt, Sheri L., Rodriguez-Galindo, Carlos, Panetta, John C., Crews, Kristine R., Wu, Jianrong, Gajjar, Amar J., Houghton, Peter J., Santana, Victor M., Stewart, Clinton F.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754908/
https://ncbi.nlm.nih.gov/pubmed/19687340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.6642
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars